Candriam SCA Portfolio holdings
Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$98.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$82.9M |
| 3 |
ServiceNow
NOW
|
+$70.4M |
| 4 |
Intel
INTC
|
+$58.4M |
| 5 |
Salesforce
CRM
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$102M |
| 2 |
Palo Alto Networks
PANW
|
+$102M |
| 3 |
AbbVie
ABBV
|
+$68.9M |
| 4 |
Amazon
AMZN
|
+$57M |
| 5 |
NVIDIA
NVDA
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.06% |
| 2 | Healthcare | 24.01% |
| 3 | Financials | 9.02% |
| 4 | Communication Services | 7.08% |
| 5 | Consumer Discretionary | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Qnity Electronics Inc
Q
$25.6B
| $43.3M | 0.19% |
342,911
+296,648
| +641% | +$38.8M |
2026 Q1
2 quarters
|
|
102
HCA Healthcare
HCA
$105B
| $43.2M | 0.19% |
100,808
-5,324
| -5% | -$2.18M |
2014 Q4
47 quarters
|
|
103
IDEAYA Biosciences
IDYA
$3.04B
| $42.8M | 0.19% |
1,110,424
+18,123
| +2% | +$684K |
2022 Q3
16 quarters
|
|
104
Zscaler
ZS
$31.5B
| $41.9M | 0.19% |
209,582
-49,003
| -19% | -$8.35M |
2020 Q2
25 quarters
|
|
105
Cytokinetics
CYTK
$7.82B
| $40.8M | 0.18% |
617,386
+174,320
| +39% | +$13.3M |
2025 Q4
3 quarters
|
|
106
FirstCash
FCFS
$7.79B
| $40.7M | 0.18% |
191,858
+12,213
| +7% | +$2.63M |
2026 Q1
2 quarters
|
|
107
RenaissanceRe
RNR
$14.3B
| $40.5M | 0.18% |
126,892
+38,201
| +43% | +$12.4M |
2026 Q1
2 quarters
|
|
108
Travelers Companies
TRV
$82.6B
| $40.3M | 0.18% |
112,673
+2,598
| +2% | +$951K |
2016 Q1
42 quarters
|
|
109
Credicorp
BAP
$29B
| $40.1M | 0.18% |
105,200
-11,200
| -10% | -$4.3M |
2024 Q4
7 quarters
|
|
110
Spyre Therapeutics
SYRE
$9.8B
| $40.1M | 0.18% |
448,570
-97,742
| -18% | -$9.4M |
2024 Q1
10 quarters
|
|
111
Royal Bank of Canada
RY
$281B
| $40M | 0.18% |
201,890
-35,483
| -15% | -$7.38M |
2014 Q4
47 quarters
|
|
112
Marriott International
MAR
$109B
| $39.5M | 0.18% |
110,606
-4,602
| -4% | -$1.64M |
2014 Q4
47 quarters
|
|
113
Enliven Therapeutics
ELVN
$3.56B
| $38.9M | 0.17% |
846,451
-59,223
| -7% | -$3.23M |
2025 Q2
5 quarters
|
|
114
PTC
PTC
$21.3B
| $38.9M | 0.17% |
276,467
+32,799
| +13% | +$4.5M |
2015 Q4
43 quarters
|
|
115
IQVIA
IQV
$44.7B
| $38.7M | 0.17% |
143,415
+3,970
| +3% | +$959K |
2015 Q4
43 quarters
|
|
116
Northern Trust
NTRS
$32.2B
| $38.5M | 0.17% |
226,760
-33,854
| -13% | -$6.19M |
2014 Q4
47 quarters
|
|
117
Moody's
MCO
$87.3B
| $38M | 0.17% |
83,324
+27,364
| +49% | +$13.3M |
2014 Q4
47 quarters
|
|
118
Trimble
TRMB
$12.8B
| $37.3M | 0.17% |
650,358
-18,811
| -3% | -$1.07M |
2018 Q3
32 quarters
|
|
119
PNC Financial Services
PNC
$91.8B
| $37.3M | 0.17% |
167,042
+11
| +0% | +$2.7K |
2014 Q4
47 quarters
|
|
120
Dell
DELL
$236B
| $37.1M | 0.16% |
68,774
-14,158
| -17% | -$6.65M |
2016 Q3
40 quarters
|
|
121
West Pharmaceutical
WST
$28.7B
| $37M | 0.16% |
99,489
+3,140
| +3% | +$1.11M |
2020 Q2
25 quarters
|
|
122
Automatic Data Processing
ADP
$122B
| $36.2M | 0.16% |
139,818
-19,464
| -12% | -$5.16M |
2016 Q1
42 quarters
|
|
123
Ameriprise Financial
AMP
$44.6B
| $36M | 0.16% |
72,765
+20,292
| +39% | +$10.9M |
2014 Q4
47 quarters
|
|
124
Elevance Health
ELV
$92.9B
| $35.6M | 0.16% |
91,310
+30,409
| +50% | +$12.1M |
2016 Q1
42 quarters
|
|
125
ARK Blockchain & Fintech Innovation ETF
ARKF
$697M
| $35.1M | 0.16% |
25,700
| – | – |
2021 Q4
19 quarters
|
|
Similar funds
Candriam SCA's Q3 2026 Portfolio in Review
As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.
- Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
- Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
- Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
- Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
- Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
- Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
- Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.
Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.